Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Mesenteric panniculitis Indication Strategy Report 2026: TNF, Trials and Deals
3 August 2026
2026 Mesenteric panniculitis indication strategy covering epidemiology, TNF biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Autoimmune pancreatitis type 1 Indication Strategy Report 2026: CD20, Trials and Deals
3 August 2026
2026 Autoimmune pancreatitis type 1 indication strategy covering epidemiology, CD20 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Median arcuate ligament syndrome Indication Strategy Report 2026: CGRP, Trials and Deals
3 August 2026
2026 Median arcuate ligament syndrome indication strategy covering epidemiology, CGRP biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Rumination syndrome Indication Strategy Report 2026: 5-HT4, Trials and Deals
3 August 2026
2026 Rumination syndrome indication strategy covering epidemiology, 5-HT4 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Superior mesenteric artery syndrome Indication Strategy Report 2026: GHRL, Trials and Deals
3 August 2026
2026 Superior mesenteric artery syndrome indication strategy covering epidemiology, GHRL biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Abdominal migraine Indication Strategy Report 2026: CGRP, Trials and Deals
3 August 2026
2026 Abdominal migraine indication strategy covering epidemiology, CGRP biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Idiopathic gastroparesis Indication Strategy Report 2026: GHRL, Trials and Deals
3 August 2026
2026 Idiopathic gastroparesis indication strategy covering epidemiology, GHRL biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Protein-losing enteropathy Indication Strategy Report 2026: VEGFR3, Trials and Deals
3 August 2026
2026 Protein-losing enteropathy indication strategy covering epidemiology, VEGFR3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Short bowel syndrome with intestinal failure Indication Strategy Report 2026: GLP-2, Trials and Deals
3 August 2026
2026 Short bowel syndrome with intestinal failure indication strategy covering epidemiology, GLP-2 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Gastroparesis diabetic Indication Strategy Report 2026: GHRL, Trials and Deals
3 August 2026
2026 Gastroparesis diabetic indication strategy covering epidemiology, GHRL biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Intestinal lymphangiectasia Indication Strategy Report 2026: VEGFR3, Trials and Deals
3 August 2026
2026 Intestinal lymphangiectasia indication strategy covering epidemiology, VEGFR3 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Collagenous colitis Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Collagenous colitis indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market attractiveness.